Avacta Group News Headlines. AVCT Share News. Financial News Articles for Avacta Group Plc Ord 10p updated throughout the day.

29 Nov 2021 10:38

FDA gives Avacta the go-ahead for US chemotherapy trials

(Sharecast News) - Clinical-stage biopharmaceutical company Avacta Group announced on Monday that the US Food and Drug Administration (FDA) has approved its investigational new drug (IND) application for its chemotherapy drug 'AVA6000'.

2 Nov 2021 11:25

Avacta and Novacyt await UK regulatory approval for Covid-19 tests

2 Nov 2021 10:21

Avacta suspends UK Covid test sales ahead of new approval

(Sharecast News) - Avacta said on Tuesday that it has suspended sales of its AffiDX Covid latest flow rapid antigen tests in the UK while it awaits new approval.

30 Sep 2021 11:14

Avacta hails "transformative" first half despite widening loss

30 Sep 2021 09:27

Avacta losses widen as development spend increases

(Sharecast News) - Clinical-stage biopharmaceutical company Avacta Group reported cash and short-term deposits of £37m at the end of its first half on Thursday, down from £54.5m a year ago and £47.9m at the start of the period.

29 Sep 2021 10:32

Avacta sees pre-clinical development milestone in LG Chem partnership

29 Sep 2021 09:26

Avacta gets undisclosed milestone payment from LG Chem

(Sharecast News) - Clinical-stage biopharmaceutical company Avacta Group announced on Wednesday that a preclinical development milestone has been achieved in its multi-target therapeutics partnership with South Korea's LG Chem Life Sciences, triggering an undisclosed milestone payment.

23 Sep 2021 15:59

UK earnings, trading statements calendar - next 7 days

2 Sep 2021 11:50

IN BRIEF: Avacta hires oncology drug developer as therapeutics CSO

18 Aug 2021 14:26

IN BRIEF: Avacta hires cancer doctor Mark Goldberg for board

11 Aug 2021 11:29

Avacta doses first patient in chemotherapy medication trial

11 Aug 2021 10:00

First patient dosed in Avacta's 'AVA6000' trial

(Sharecast News) - Clinical-stage oncology drug company Avacta Group announced on Wednesday that the first patient has been dosed in its phase 1 multicentre trial evaluating 'AVA6000', which it described as a "novel pro-drug" of 'doxorubicin', and its first therapeutic product based on the proprietary 'preCISION' technology.

4 Aug 2021 17:53